Two new drugs, Dapivirine and R165335, have shown great promise in Phase I and II clinical trials against drug-resistant HIV strains. These compounds are derived from the dianilinopyrimidine family and have been tested as a viable candidate for treating AIDS in developing countries.
Research suggests that social activism in groups like ACT UP can help individuals with AIDS and HIV cope better with their medical and psychological problems. Activist group members tend to use more problem-focused coping, have greater knowledge of treatment information sources, and are more integrated into support networks.
A UCLA study found that treating more people in developing countries with antiretroviral drug therapy can eliminate HIV on a community level, even without eradicating it in individuals. The research suggests that treatment and prevention are not two separate approaches, but rather intertwined strategies to save lives.
A new study found that 96% of HIV-positive MSM with STIs had received healthcare in the previous six months, highlighting the need for regular screening and effective risk reduction messages. The study also revealed high rates of co-infections with HSV-2 and syphilis among HIV-infected men.
A recent study by Emory University Health Sciences Center found that lower levels of social capital are associated with higher rates of sexually transmitted diseases. The research, which analyzed data from 48 US states, discovered that social capital is a significant predictor of infectious diseases including AIDS and STDs.
Researchers analyzed data from over 12,000 adult patients starting HAART, finding that those with more advanced disease had a higher risk of progression to AIDS or death. Early initiation of treatment was associated with reduced mortality rates, particularly for those with lower CD4 counts.
A Franco-Senegalese research team has demonstrated the efficacy of antiretroviral therapy in Africa, contrary to previous doubts. The 18-month pilot scheme showed strong adherence and high patient respect for prescriptions, with improved treatment outcomes.
NIAID-funded studies explore dual protease inhibitors, herpes simplex virus 2 risk factor for HIV infection in India, and anti-HIV antibodies' influence on HIV evolution. The conference also features the world's largest preventive HIV vaccine trial.
Scientists followed nearly 2,000 HIV-infected patients with varying levels of hepatitis C exposure. They found that exposure to hepatitis C did not increase risk of death or AIDS progression but was associated with lower antiretroviral therapy prescriptions, which may lead to increased mortality rates in this group.
A recent study in rural Uganda found a significant decline in HIV-1 incidence rates between 1990 and 1999, with a notable decrease in the second half of the decade. The reduction was particularly pronounced among men aged 20–24 years and women aged 13–19 years. This finding suggests that targeted interventions may be effective in slowi...
A five-year, $14.8 million NIH-funded award will support HIV/AIDS research in China, focusing on epidemiologic and behavioral interventions, pathogenesis of the virus, safety and efficacy of anti-HIV drugs, and vaccine development. The award aims to improve HIV/AIDS treatment and prevention measures in resource-limited countries.
The HVDDT program aims to bring a safe and effective HIV vaccine closer to reality by partnering academic research centers with private industry. Early tests in monkeys showed promising results, with vaccinated animals developing strong immune responses that protected against disease.
Researchers are making progress in developing preventive HIV vaccines, with six potential candidates tested in clinical trials over the past five years. The National Institute of Allergy and Infectious Diseases is currently sponsoring multiple clinical trials, which will require tens of thousands of additional volunteers.
The GlaxoSmithKline Drug Discovery and Development Award provides funding for innovative HIV/AIDS research, including therapies aimed at treating infection and preventing transmission. The award is intended to further the development of inventive treatments for HIV/AIDS.
A study assessing existing data on HIV/AIDS interventions found that cost-effectiveness varies greatly between interventions. Some interventions, such as selective blood safety measures and targeted condom distribution, can prevent a case of HIV/AIDS for under $11 and gain over $1 in disability-adjusted life-years (DALYs) per dollar spent
Women in jail have high HIV infection rates, with specific risk factors identified as substance abuse disorders and severe mental illness. An HIV/AIDS education program in a correctional setting has shown promise in reducing the spread of HIV in communities.
A significant proportion of elderly people in the UK experience poor hearing, with around a quarter failing a whispered voice test. The study highlights challenges in improving detection and management of reduced hearing, as well as increasing ownership and use of hearing aids.
A new oral medication, valganciclovir, has been shown to be as effective as traditional intravenous treatment for CMV retinitis in AIDS patients. The pill form reduces the need for permanent catheters and improves patient convenience.
Researchers found that two American infants were infected with African strains of HIV as early as 1994. The study suggests that more complicated regimens work best to combat the spread of HIV in pediatric patients, but may pose social problems for children entering adolescence.
A University of Florida researcher has developed a feline AIDS vaccine that the federal government has approved for commercial use. The vaccine, expected to be available this summer, is based on viruses from long-term nonprogressor cats and may aid in human HIV development.
The University of Illinois Chicago College of Nursing has launched a five-year AIDS prevention project in Malawi, training health workers to become leaders in combating the pandemic. The project aims to educate hospital staff, nurses, and medical officers on HIV transmission and safe-sex practices, as well as mobilizing community peer ...
The Pediatric AIDS Clinical Trials Group will support clinical trials sites, a statistical center, and operations center with renewed funding. The new agenda emphasizes five key areas: perinatal transmission, pediatric treatment, adolescent treatment, long-term evaluation of antiretroviral therapies, and domestic and international coll...
The HIV/AIDS epidemic in Mozambique is taking a toll on education, leading to reduced school enrollments, graduation rates, and quality of education. The report predicts that the country's economy will be smaller than expected by 2010 due to reduced productivity growth, population growth, human capital accumulation, and physical capita...
The SMART trial aims to find a balance between aggressive HIV treatment and minimizing adverse side effects. The study will compare two distinct treatment approaches over an average of seven years, providing valuable insights into the optimal use of antiviral therapy.
A Mayo Clinic case study describes a patient with progressive multifocal leukoencephalopathy (PML) who responded positively to HAART-cidofovir combination therapy, regaining mobility and daily functioning. The case contributes to growing data on effective treatment strategies for PML in AIDS patients.
Recent research from San Francisco Veterans Affairs Medical Center suggests a closer connection between HIV and Alzheimer's disease. The study found that immune cell markers of AIDS dementia remain even after treatment with anti-retroviral drug cocktails, similar to those elevated in patients with Alzheimer's disease.
A unique partnership between Imperial College London and the International AIDS Vaccine Initiative aims to combat the HIV epidemic. The laboratory will evaluate work from worldwide HIV/AIDS vaccine trials, promoting standardization and facilitating the development of effective vaccines.
Researchers have found that protease inhibitors used in AIDS treatment can lead to severe cardiovascular problems by accumulating a certain apolipoprotein in liver cells. This accumulation causes the liver cell to release excessive lipoprotein particles into the bloodstream, increasing the risk of heart disease.
A study found significant disparities in HIV/AIDS treatment among minority Medicaid recipients, with African Americans waiting longer to start life-saving treatments and Hispanics being less likely to stay on them. The researchers suggest that improved care strategies and supportive services are needed to address these disparities.
The North-Central California Center for AIDS Research aims to address HIV infection patterns, develop prevention strategies and improve treatment outcomes. The center will foster collaboration between researchers and clinicians to advance knowledge of HIV and its impact on rural communities.
The study aims to determine the effectiveness of meditation and/or massage in improving patients' perceived quality of life. Researchers hope to find ways to improve quality of life, particularly in the spiritual domain, for patients dying with AIDS.
A Yale study found that HIV patients who trust their physicians are 20% more likely to adhere to their treatment regimens. Lack of social support and mistrust in peers also hinder adherence to ART.
A study of 13 HIV-positive men found that those with high levels of autonomic nervous system activity responded less well to antiretroviral treatment, with some experiencing no immune recovery. Stress accelerates AIDS progression by increasing viral replication and making it harder for the body to fight off the infection.
The US FDA's priority review process for cancer drugs is significantly faster than its European counterpart, EMEA. In contrast to the EMEA's average approval time of over two years, the FDA approves cancer drugs on average within six months.
Local experts urge a $300 million increase in Ryan White/CARE Act funding to ensure stable medical care and treatment for newly diagnosed patients. HIV infection can be managed as a chronic disease with access to services and new anti-AIDS drugs.
A study finds that alcohol consumption is associated with unsafe sex among injection drug users, leading to increased HIV transmission risk. The research suggests that addressing alcohol use and disorders in this population is crucial for preventing the spread of HIV.
A new AIDS vaccine developed by Yale researchers has shown promising results in protecting monkeys from the disease. The vaccine, which uses a common livestock virus vector, was highly effective in animal models and protected vaccinated monkeys for up to 14 months.
A study by Johns Hopkins Bloomberg School of Public Health found that nearly one third of eligible injection drug users never received antiretroviral treatment. Methadone addiction treatment, health insurance, and regular access to care were associated with increased HAART use among men.
New study reveals how HIV subverts the immune system by mimicking other enemy invaders, rendering T cells unable to detect infection and cancer. This understanding will aid in developing new AIDS therapies targeting vulnerable points of HIV infection.
A genetic mutation in the CCR5 gene provides protection against HIV infection, slowing the spread of AIDS in African populations. Studies suggest that this mutation may be more common in European populations due to historical epidemics.
Researchers at the University of Maryland Biotechnology Institute have engineered rats to contain the genome of HIV-1, making them a valuable model for studying AIDS-related diseases. The rats develop clinical signs similar to those of AIDS in humans, including neurological abnormalities and organ damage.
Researchers have developed a new HIV vaccine that provides full protection against vaginal transmission of an HIV-like virus. The vaccine combines elements of the successful Sabin oral poliovirus vaccine with genetic fragments of the AIDS virus, triggering a robust immune response.
Researchers found that HAART decreased the HIV death rate to 38 percent of pre-HAART levels and opportunistic infections to 66 percent, supporting its effectiveness in advanced patients. The study analyzed data from 528 advanced AIDS patients who received HAART for an average of 15 months.
The UNC-CH AIDS clinic in Robeson County offers treatment and care to HIV-positive patients near their homes, addressing a significant problem in the area's high sexually transmitted disease rates. The clinic is supported by a $100,000 grant and covers costs for indigent patients through Medicaid and private insurance.
Researchers identified a polyoxometalate (POM) molecule that inhibits HIV protease, providing a potential second line of attack against the virus. The discovery could lead to reduced spread of drug-resistant strains and delayed onset of full-blown AIDS.
Jay Levy, MD, argues that an HIV vaccine aiming to reduce virus levels in blood and genital fluids could play a crucial role in controlling the epidemic. This approach would delay disease development and suppress the virus worldwide, rather than achieving sterilizing immunity.
The NIH has announced a new initiative and strategic plan for global AIDS research, with the goal of slowing the pandemic and reversing its destruction. The plan includes increased investment in global research, new funding approaches, and support for long-term research infrastructure.
Researchers at the University of Georgia are developing two prevention programs aimed at reducing alcohol and substance use among rural African-American children. The projects, led by Dr. Gene Brody and Dr. Velma McBride Murry, will focus on strengthening family and cognitive processes to foster competencies and deter substance abuse.
A study published in the journal AIDS identifies a genetic risk factor for HIV infection, specifically a variation in the RANTES gene that increases susceptibility but also slows down disease progression. Researchers found that this SNP is associated with up to twice the risk of HIV infection and takes about 40% longer to develop AIDS.
A Cornell University parent-education program has shown that it can triple the likelihood of parents discussing HIV risk reduction with their children. The program also significantly increases the likelihood that parents will make personal risk behavior changes and obtain HIV testing. The study, which involved 375 parents in New York C...
Researchers argue that current HIV prevention resource allocations are not consistent with trends in the spread of HIV disease. They propose a shift in focus from AIDS case-based reporting to sentinel surveillance systems, citing data showing declining HIV prevalence and incidence among heterosexuals and stable rates among MSMs.
Robert C. Gallo and Luc Montagnier receive Spain's top science award for their groundbreaking work on the diagnosis, prevention, and treatment of HIV/AIDS. The Prince of Asturias Award recognizes their originality and relevance to the scientific community.
The AAPS Annual Meeting highlights the growing burden of non-communicable diseases, with new treatments offering hope for patients. The meeting showcases innovative therapies, including an inhalable flu vaccine and a new AIDS medication regimen.
The Fogarty International Center has awarded a total of $15 million to support six new awards, three competing renewal awards, and 32 competing supplements for U.S. universities under the AITRP. The program focuses on building global HIV/AIDS research capacity and preventing HIV transmission in developing countries.
A DNA vaccine paired with an immune protein successfully controls a highly pathogenic AIDS virus in monkeys, strengthening their immune response and preventing disease. The approach could decrease HIV-1 transmission rates by reducing viral replication in vaccinated individuals.
Researchers at Beth Israel Deaconess Medical Center developed an AIDS vaccine that harnesses "killer" T cells to suppress the virus and prevent clinical disease in monkeys. The vaccine showed significant success in boosting CD8 cytotoxic T lymphocytes, which can attack and contain HIV-infected cells.
Harbor Branch researchers have isolated compounds from an Indian Ocean sponge that show promise as a new treatment for fungal infections, including those affecting AIDS patients. The discovery of unique cyclic peroxy acids may provide a more effective alternative to existing antifungal agents.
A shorter course of AZT therapy can reduce HIV transmission from mothers to children, now available at a lower cost. The study found that treatment regimens starting at 28 weeks pregnant and given to the infant for six weeks resulted in a transmission rate similar to standard long/long treatment.
At the Institute of Human Virology (IHV) conference, scientists from Africa, Caribbean, and US/Europe discussed HIV/AIDS challenges in the developing world. They emphasized the need for more North-South partnerships to address affordable therapies and preventative vaccines.
Researchers describe a medical paradox where some AIDS patients develop opportunistic infections after regaining immune strength from HAART therapy. The 'immune reconstitution disease syndrome' occurs when the strengthened immune system reacts to bacteria or viruses already present in the patient.